Clinical Trial Update: Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial assessing safety, tolerability, and pharmacokinetics of isoniazid and rifapentine regimens (1 month daily or 3 months weekly) with dolu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• Dolutegravir (dolutegravir)
• ISONIAZID (ISONIAZID)
• rifapentine (rifapentine)

Snippet

Sponsor: The Aurum Institute NPC | Conditions: HIV Seropositivity, Pregnancy | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING